OPPM
Opus Point Partners Management Portfolio holdings
AUM
$46.9M
This Quarter Return
+2.69%
1 Year Return
-4.17%
3 Year Return
+83.22%
5 Year Return
+175.29%
10 Year Return
–
AUM
$47.7M
AUM Growth
+$47.7M
(-50%)
Cap. Flow
-$50.4M
Cap. Flow
% of AUM
-105.77%
Top 10 Holdings %
Top 10 Hldgs %
55.31%
Holding
62
New
1
Increased
14
Reduced
32
Closed
10
Top Buys
| 1 |
ProShares Ultra NASDAQ Biotechnology
BIB
|
$3.14M |
| 2 |
Acadia Pharmaceuticals
ACAD
|
$670K |
| 3 |
FibroGen
FGEN
|
$641K |
| 4 |
ALXN
Alexion Pharmaceuticals Inc
ALXN
|
$479K |
| 5 |
TSRO
TESARO, Inc.
TSRO
|
$371K |
Top Sells
| 1 |
Nektar Therapeutics
NKTR
|
$7.29M |
| 2 |
Bristol-Myers Squibb
BMY
|
$5.52M |
| 3 |
Merck
MRK
|
$4.71M |
| 4 |
RXDX
Ignyta, Inc.
RXDX
|
$4.55M |
| 5 |
AstraZeneca
AZN
|
$4.16M |
Sector Composition
| 1 | Healthcare | 68.52% |
| 2 | Real Estate | 0% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Shares Change % | Capital Flow | |
|---|---|---|---|---|---|---|
|
TSRO
26
DELISTED
TESARO, Inc.
TSRO
| $657K | 1.29% | 11,500 +6,500 | +130% | +$371K |
|
|
CKPT
27
DELISTED
Checkpoint Therapeutics
CKPT
| $495K | 0.97% | 112,760 | – | – |
|
28
Akebia Therapeutics
AKBA
$833M
| $477K | 0.94% | 50,004 +28,995 | +138% | +$277K |
|
29
ProQR Therapeutics
PRQR
$237M
| $473K | 0.93% | 153,846 -153,846 | -50% | -$473K |
|
30
Pacira BioSciences
PCRX
$1.2B
| $389K | 0.76% | 12,500 -12,500 | -50% | -$389K |
|
31
Ultragenyx Pharmaceutical
RARE
$2.89B
| $372K | 0.73% | 7,291 -1,181 | -14% | -$60.3K |
|
|
ADMS
32
DELISTED
Adamas Pharmaceuticals, Inc.
ADMS
| $359K | 0.7% | 15,000 -15,000 | -50% | -$359K |
|
33
Axsome Therapeutics
AXSM
$6.05B
| $327K | 0.64% | 133,500 | – | – |
|
34
Bio-Techne
TECH
$8.5B
| $303K | 0.59% | 2,009 +22 | +1% | +$3.32K |
|
35
United Therapeutics
UTHR
$13.8B
| $290K | 0.57% | 2,579 +529 | +26% | +$59.5K |
|
36
Grifois
GRFS
$6.78B
| $285K | 0.56% | 13,422 +1,857 | +16% | +$39.4K |
|
37
IQVIA
IQV
$32.4B
| $283K | 0.56% | 2,889 +474 | +20% | +$46.4K |
|
38
Precigen
PGEN
$1.34B
| $283K | 0.56% | 18,478 +4,257 | +30% | +$65.2K |
|
|
AVXS
39
DELISTED
AveXis, Inc. Common Stock
AVXS
| $281K | 0.55% | 2,275 -225 | -9% | -$27.8K |
|
40
Charles River Laboratories
CRL
$8.04B
| $279K | 0.55% | 2,613 +459 | +21% | +$49K |
|
|
ICPT
41
DELISTED
Intercept Pharmaceuticals, Inc.
ICPT
| $277K | 0.54% | 4,496 +717 | +19% | +$44.2K |
|
42
Gilead Sciences
GILD
$140B
| $276K | 0.54% | 3,667 +592 | +19% | +$44.6K |
|
43
Neurocrine Biosciences
NBIX
$13.8B
| $268K | 0.53% | 3,232 -972 | -23% | -$80.6K |
|
|
PRTK
44
DELISTED
Paratek Pharmaceuticals, Inc.
PRTK
| $260K | 0.51% | 20,000 -20,000 | -50% | -$260K |
|
|
MDCO
45
DELISTED
Medicines Co
MDCO
| $231K | 0.45% | 7,000 -7,000 | -50% | -$231K |
|
|
BLUE
46
DELISTED
bluebird bio
BLUE
| $226K | 0.44% | +1,326 | New | +$226K |
|
|
SCTL
47
DELISTED
Societal CDMO, Inc. Common Stock
SCTL
| $139K | 0.27% | 12,615 -12,616 | -50% | -$139K |
|
|
CFRX
48
DELISTED
ContraFect Corporation
CFRX
| $122K | 0.24% | 75,000 -75,000 | -50% | -$122K |
|
|
PGNX
49
DELISTED
Progenics Pharmaceuticals Inc
PGNX
| $81K | 0.16% | 10,891 -10,891 | -50% | -$81K |
|
50
SCYNEXIS
SCYX
$34.9M
| $45K | 0.09% | 33,304 -33,304 | -50% | -$45K |
|